

**Regd. Office and works:**

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231  
Pithampur - 454775, Dist. Dhar  
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- [investors@medicaps.com](mailto:investors@medicaps.com)Web site:- [www.medicaps.com](http://www.medicaps.com)**MCL/SE/2024-2025****Date: 23<sup>rd</sup> May, 2024****Online filing at: [www.listing.bseindia.com](http://www.listing.bseindia.com)**

To,  
The General Manager  
DCS-CRD  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street Fort, Mumbai 400001(M.H.)

**BSE Scrip Code: 523144, ISIN: INE442D01010****Subject: Outcome of Board meeting held on Thursday 23<sup>rd</sup> May, 2024 pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015.**

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company in their meeting held on today i.e. **Thursday, 23<sup>rd</sup> day of May, 2024**, has inter alia considered and approved the following businesses:

- a) Audited Standalone and Consolidated Financial Results for the Fourth Quarter as well as year ended 31<sup>st</sup> March, 2024 along with the Auditors Report thereon, Statement of Assets and Liabilities, and Cash Flow Statement.
- b) Declaration regarding unmodified opinion of the Auditors on Annual Audited Financial Results of the Company pursuant to second proviso of Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.
- c) Re-Appointment of L.N. Joshi & Company, Practicing Company Secretaries as Secretarial Auditor of the Company for Financial Year 2024-25.
- d) Re-Appointment of Praveen Shrivastava & Company Chartered Accountants as an Internal Auditor of the Company for Financial Year 2024-25.
- e) Other routine businesses with the permission of Chair.

Further, copy of aforesaid Audited Financial results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid Audited Financial Results shall be uploaded on Stock Exchange website at [www.bseindia.com](http://www.bseindia.com) and on the website of the Company at [www.medicaps.com](http://www.medicaps.com). Further, the extracts of the above audited financial results will be published in Hindi and English Newspaper.

Further, Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 with reference to re-appointment of Secretarial Auditor and Internal Auditor of the Company are being filed separately.

**Regd. Office and works:**

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231  
Pithampur - 454775, Dist. Dhar  
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- [investors@medicaps.com](mailto:investors@medicaps.com)

Web site:- [www.medicaps.com](http://www.medicaps.com)

---

The Meeting of the Board of Directors commenced at 3.00 P.M. and concluded at 05:35 P.M.

You are requested to please take on record the same.

Thanking You,

**FOR, MEDI-CAPS LIMITED**

**ALOK K GARG**  
**MANAGING DIRECTOR**  
**DIN: 00274321**

Independent Auditor's Report on the Quarterly and Year to date Audited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI {Listing Obligations and Disclosure Requirements} Regulations, 2015, as amended ('Listing Regulations')

To,  
**The Board of Directors**  
**MEDICAPS LIMITED**

**Report on the audit of the Standalone Financial Results**


**Opinion**

We have audited the accompanying standalone quarterly financial results of Medi-Caps Limited (hereinafter referred to as the 'Company') for the quarter and year ended March 31, 2024, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

a) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

b) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024 and its profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.



## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of Standalone Financial Results" section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion. Our opinion is not modified in respect of this matter.

## **Management's Responsibilities for the Standalone Financial Results**

The quarterly financial results as well as the year to date standalone financial results has been prepared on the basis of Standalone Annual Financial Statements.

The Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial results that give a true and fair view of the net profit including other comprehensive income, changes in equity and cash flows and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.





In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to these risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
4. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material



uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The Statement includes the results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.

**Place:** Indore


**Date:** 23-05-2024

**UDIN:** 24429040BKESFL7519

**For Rawka & Associates**

Chartered Accountants

FRN: 021606C



**(Venus Rawka)**

Partner

M. No.: 429040

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435  
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2024**


(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended			Year Ended	
		03 Month Ended 31.03.2024	Preceeding 03 Month Ended 31.12.2023	Corresponding 03 Month Ended in the previous year 31.03.2023	Year to date figure for current year 31.03.2024	Previous Year Ended 31.03.2023
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>I</b>	<b>Revenue from Operation</b>					
	(a) Net sales	184.29	298.09	0.00	693.03	0.00
	(b) Other operating income	12.63	6.65	6.22	23.51	10.14
	<b>Revenue from Operation</b>	<b>196.92</b>	<b>304.74</b>	<b>6.22</b>	<b>716.54</b>	<b>10.14</b>
<b>II</b>	<b>Other Income</b>	<b>13.69</b>	<b>0.24</b>	<b>2.59</b>	<b>14.72</b>	<b>64.46</b>
<b>III</b>	<b>Total Income (I+II)</b>	<b>210.61</b>	<b>304.98</b>	<b>8.81</b>	<b>731.26</b>	<b>74.60</b>
<b>IV</b>	<b>Expenses</b>					
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.36	0.51	0.00	1.20	0.00
	d) Employee benefits expense	42.27	28.86	5.71	82.88	23.27
	e) Finance costs	0.00	0.00	0.00	0.00	0.00
	f) Depreciation and amortisation expense	4.00	4.00	2.31	16.01	9.23
	g) Power Cost	0.16	0.09	0.02	0.43	0.21
	h) Freight Exp.	0.00	0.00	0.00	0.00	0.00
	i) Other expenses	49.70	57.91	3.78	148.01	16.32
	<b>Total Expenses (IV)</b>	<b>96.49</b>	<b>91.37</b>	<b>11.82</b>	<b>248.53</b>	<b>49.03</b>
<b>V</b>	<b>Profit/(Loss) before exceptional item &amp; tax (III-IV)</b>	<b>114.12</b>	<b>213.61</b>	<b>-3.01</b>	<b>482.73</b>	<b>25.57</b>
<b>VI</b>	<b>Exceptional items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>VII</b>	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>114.12</b>	<b>213.61</b>	<b>-3.01</b>	<b>482.73</b>	<b>25.57</b>
<b>VIII</b>	<b>Tax expense</b>					
	1) Current Tax	50.00	45.00	0.00	95.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	0.00	0.00
	3) Deferred Tax	-1.09	0.00	-0.14	-1.09	-0.14
	<b>Total Tax Expenses</b>	<b>48.91</b>	<b>45.00</b>	<b>-0.14</b>	<b>93.91</b>	<b>-0.14</b>
<b>IX</b>	<b>Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>X</b>	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>65.21</b>	<b>168.61</b>	<b>-2.87</b>	<b>388.82</b>	<b>25.71</b>
<b>XI</b>	<b>Profit/(loss) from discontinued operations</b>	<b>0.00</b>	<b>0.00</b>	<b>-1.36</b>	<b>0.00</b>	<b>-11.07</b>
<b>XII</b>	<b>Tax expense of discontinued operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>XIII</b>	<b>Profit/(loss) from Discontinued operations (after tax) (XI-XII)</b>	<b>0.00</b>	<b>0.00</b>	<b>-1.36</b>	<b>0.00</b>	<b>-11.07</b>
<b>XIV</b>	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>XV</b>	<b>Profit/(loss) for the period (X+XIII)</b>	<b>65.21</b>	<b>168.61</b>	<b>-4.23</b>	<b>388.82</b>	<b>14.64</b>
<b>XVI</b>	<b>Other comprehensive income</b>					
	(a) (i) items that will not be reclassified to statement of profit & loss	28.05	51.38	-1.38	149.36	-32.70
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00
	<b>Other comprehensive income :</b>	<b>28.05</b>	<b>51.38</b>	<b>-1.38</b>	<b>149.36</b>	<b>-32.70</b>
<b>XVII</b>	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>93.26</b>	<b>219.99</b>	<b>-5.61</b>	<b>538.18</b>	<b>-18.06</b>
<b>XVIII</b>	<b>Profit or Loss Attributable to</b>					
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00
<b>XIX</b>	<b>Total Comprehensive Income for the period Attributable to</b>					
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00

XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	5401.93	4863.75
XXII	Earnings per equity share (for continuing operation)					
	a) Basic (Rs.)	0.52	1.35	-0.02	3.12	0.21
	b) Diluted (Rs.)	0.52	1.35	-0.02	3.12	0.21
XXIII	Earnings per equity share (for discontinued operation)					
	a) Basic (Rs.)	0.00	0.00	-0.01	0.00	-0.09
	b) Diluted (Rs.)	0.00	0.00	-0.01	0.00	-0.09
XXIV	Earnings per equity share (for discontinued and continuing operation)					
	a) Basic (Rs.)	0.52	1.35	-0.03	3.12	0.12
	b) Diluted (Rs.)	0.52	1.35	-0.03	3.12	0.12

DATE: 23.05.2024  
PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED



**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321

Independent Auditor's Report on the Quarterly and Year to date Audited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations')

## TO THE BOARD OF DIRECTORS OF MEDICAPS LIMITED

### Report on the audit of the Consolidated Financial Results

#### Opinion

We have audited the accompanying statement of quarterly and year to date consolidated financial results of **MEDICAPS LIMITED** (hereinafter referred to as the 'Holding Company') and its wholly owned subsidiary **MEDGEL PRIVATE LIMITED** (the holding company and its subsidiary together referred to as "the group") for the quarter ended on March 31, 2024 and for the year to date results for the period from April 01, 2023 to March 31, 2024 ("Statement"), attached herewith, being submitted by the holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- A) Includes the results of the Holding Company and its wholly owned Subsidiary.
- B) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- C) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024 and its profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.





## **Basis for Opinion**


We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion. Our opinion is not modified in respect of this matter.

## **Management's Responsibilities for the consolidated Financial Results**

The quarterly financial results as well as the year to date consolidated financial results has been prepared on the basis of Consolidated Annual Financial Statements.

The Holding Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Consolidated Financial Results that give a true and fair view of the net profit including other comprehensive income, changes in equity and cash flows and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.




In preparing Consolidated Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to these risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
4. Conclude on the appropriateness of the Board of Directors' of the Holding Company use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.





obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

5. Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient appropriate audit evidence regarding the financial information of the Entity within the group to express an opinion on the Consolidated Financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matters**

The accompanying Consolidated Financial Results include the Financial Results and other information of 1 subsidiary Medgel Private Limited which reflect total assets of **Rs. 7387.47 lacs** as at March 31st, 2024, total revenue of **Rs. 2050.76 lacs**, total cash outflow of **Rs. -79.71 lacs** for the year ended on that date which have been audited by us.

The Consolidated Financial Statements includes the results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024 and the published unaudited year to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of this matter.

**Place:** Indore

**Date:** 23-05-2024

**UDIN:** 24429040BKESFM1126

**For Rawka & Associates**

Chartered Accountants

FRN: 021606C



**Venus Rawka**

Partner

M. No. : 429040

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435  
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2024**


(Amount in Laes except EPS)

S.N.	Particulars	Quarter Ended			Year Ended	
		03 Month Ended 31.03.2024	Preceeding 03 Month Ended 31.12.2023	Corresponding 03 Month Ended in the previous year 31.03.2023	Year to date figure for current year ended 31.03.2024	Previous Year Ended 31.03.2023
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
<b>I</b>	<b>Revenue from Operation</b>					
	(a) Net sales	741.84	692.38	1018.37	2656.35	4857.75
	(b) Other operating income	45.07	14.65	38.54	78.16	79.35
	<b>Revenue from Operation</b>	<b>786.91</b>	<b>707.03</b>	<b>1056.91</b>	<b>2734.51</b>	<b>4937.10</b>
<b>II</b>	<b>Other Income</b>	24.28	9.07	23.83	47.50	160.32
<b>III</b>	<b>Total income (I+II)</b>	<b>811.19</b>	<b>716.10</b>	<b>1080.74</b>	<b>2782.01</b>	<b>5097.42</b>
<b>IV</b>	<b>Expenses</b>					
	a) Cost of material consumed	198.85	247.64	484.82	842.84	2205.25
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	74.31	-36.50	-111.24	108.91	85.21
	d) Employee benefits expense	207.57	146.84	221.52	706.88	768.92
	e) Finance costs	0.00	0.00	0.01	0.00	0.16
	f) Depreciation and amortisation expense	32.83	45.27	22.06	168.65	174.32
	g) Power Cost	37.18	32.78	61.53	148.15	216.22
	h) Freight Exp.	58.78	57.86	110.53	153.52	505.30
	i) Other expenses	260.57	188.07	212.08	777.66	649.97
	<b>Total Expenses (IV)</b>	<b>870.09</b>	<b>681.96</b>	<b>1001.31</b>	<b>2906.61</b>	<b>4605.35</b>
<b>V</b>	<b>Profit/(Loss) before exceptional item &amp; tax (III-IV)</b>	<b>-58.90</b>	<b>34.14</b>	<b>79.43</b>	<b>-124.60</b>	<b>492.07</b>
<b>VI</b>	<b>Exceptional items</b>	0.00	0.00	0.00	0.00	0.00
<b>VII</b>	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>-58.90</b>	<b>34.14</b>	<b>79.43</b>	<b>-124.60</b>	<b>492.07</b>
<b>VIII</b>	<b>Tax expense</b>					
	1) Current Tax	50.00	45.00	42.00	95.00	122.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	5.56	0.00	5.56	183.58
	3) Deferred Tax	-1.09	0.00	-0.14	-1.09	-0.14
	<b>Total Tax Expenses</b>	<b>48.91</b>	<b>50.56</b>	<b>41.86</b>	<b>99.47</b>	<b>305.44</b>
<b>IX</b>	<b>Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>X</b>	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-107.81</b>	<b>-16.42</b>	<b>37.58</b>	<b>-224.08</b>	<b>186.63</b>
<b>XI</b>	<b>Profit/(loss) from discontinued operations</b>	0.00	0.00	-1.36	0.00	-11.07
<b>XII</b>	<b>Tax expense of discontinued operations</b>	0.00	0.00	0.00	0.00	0.00
<b>XIII</b>	<b>Profit/(loss) from Discontinued operations (after tax) (XI-XII)</b>	<b>0.00</b>	<b>0.00</b>	<b>-1.36</b>	<b>0.00</b>	<b>-11.07</b>
<b>XIV</b>	<b>Share of profit (loss) of associates and joint ventures accounted for using equity method</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>XV</b>	<b>Profit/(loss) for the period (X+XIII)</b>	<b>-107.81</b>	<b>-16.42</b>	<b>36.22</b>	<b>-224.08</b>	<b>175.56</b>
<b>XVI</b>	<b>Other comprehensive income</b>					
	(a) (i) items that will not be reclassified to statement of profit & loss	100.21	136.81	24.17	465.27	55.95
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00
	<b>Other comprehensive income :</b>	<b>100.21</b>	<b>136.81</b>	<b>24.17</b>	<b>465.27</b>	<b>55.95</b>
<b>XVII</b>	<b>Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)</b>	<b>-7.60</b>	<b>120.39</b>	<b>60.39</b>	<b>241.20</b>	<b>231.51</b>
<b>XVIII</b>	<b>Profit or Loss Attributable to</b>					
	Profit or Loss Attributable to owners of Parents	-107.81	-16.42	36.22	-224.08	175.56
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00
<b>XIX</b>	<b>Total Comprehensive Income for the period Attributable to</b>					
	Total Comprehensive Income for the period Attributable to owners of Parents	-7.60	120.39	60.39	241.20	231.51
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00

XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	10851.33	10610.14
XXII	Earnings per equity share (for continuing operation)					
	a) Basic (Rs.)	-0.86	-0.13	0.30	-1.80	1.50
	b) Diluted (Rs.)	-0.86	-0.13	0.30	-1.80	1.50
XXIII	Earnings per equity share (for discontinued operation)					
	a) Basic (Rs.)	0.00	0.00	-0.01	0.00	-0.09
	b) Diluted (Rs.)	0.00	0.00	-0.01	0.00	-0.09
XXIV	Earnings per equity share (for discontinued and continuing operation)					
	a) Basic (Rs.)	-0.86	-0.13	0.29	-1.80	1.41
	b) Diluted (Rs.)	-0.86	-0.13	0.29	-1.80	1.41

DATE: 23.05.2024  
PLACE: INDORE

For and on behalf of board of directors of  
MEDICAPS LIMITED



**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321

**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435

Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

**AUDITED STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH 2024**

The standalone and Consolidated Statement of Assets & Liabilities is as under:		(Amount in Lacs)			
		Standalone		Consolidated	
Particulars	As at		As at		
	31-03-2024	31-03-2023	31-03-2024	31-03-2023	
	Audited	Audited	Audited	Audited	
<b>I. Assets</b>					
<b>(1) Non-Current Assets</b>					
(a) Property, Plant and Equipment	226.12	246.49	2942.66	3076.73	
(b) Capital work-in-progress	0.00	0.00	0.00	0.00	
(c) Goodwill	0.00	0.00	2814.15	2814.15	
(c) Investment Property	0.00	0.00	0.00	0.00	
(d) Financial Assets					
(i) Investments	4390.58	4390.67	931.90	648.73	
(e) Other non-current assets	4.93	4.91	38.73	38.58	
<b>Sub Total - Non-Current Assets</b>	<b>4621.63</b>	<b>4642.07</b>	<b>6727.44</b>	<b>6578.19</b>	
<b>(2) Current assets</b>					
(a) Inventories	3.16	0.00	573.59	706.90	
(b) Financial Assets					
(i) Investments	1120.25	806.90	3014.33	2558.70	
(ii) Trade receivables	465.04	223.82	1081.72	846.44	
(iii). Cash and cash equivalents	4.54	4.05	32.14	111.36	
(iv) Bank balances other than (iii) above	0.00	0.00	0.00	0.00	
(c) Other current assets	594.60	485.70	1299.27	1797.05	
<b>Sub Total - Current Assets</b>	<b>2187.59</b>	<b>1520.47</b>	<b>6001.05</b>	<b>6020.45</b>	
<b>Total Assets</b>	<b>6809.22</b>	<b>6162.54</b>	<b>12728.49</b>	<b>12598.64</b>	
<b>II. EQUITY AND LIABILITIES</b>					
<b>EQUITY</b>					
(a) Equity Share Capital	1247.00	1247.00	1247.00	1247.00	
(b) Other Equity	5401.93	4863.75	10851.33	10610.14	
<b>Sub Total - Equity</b>	<b>6648.93</b>	<b>6110.75</b>	<b>12098.33</b>	<b>11857.14</b>	
<b>LIABILITIES</b>					
<b>(1) Non-Current Liabilities</b>					
(a) Financial Liabilities	0.00	0.00	0.00	0.00	
(b) Provisions	0.00	0.00	61.31	58.87	
(c) Deferred tax liabilities (Net)	42.89	43.98	42.89	43.98	
<b>Sub Total - Non-Current Liabilities</b>	<b>42.89</b>	<b>43.98</b>	<b>104.20</b>	<b>102.85</b>	
<b>(2) Current Liabilities</b>					
(a) Financial Liabilities					
(i) Borrowings	0.00	0.00	0.00	0.00	
(ii) Trade payables					
a) total outstanding dues of micro enterprises and small enterprises; and					
b) total outstanding dues of creditor other than micro enterprises and small enterprises;	0.50	0.00	182.53	282.94	
(iii) Other financial liabilities (other than those specified in item (b),	0.00	0.00	0.00	0.00	
(b) Other current liabilities	21.90	7.81	248.43	233.71	
(c) Provisions	0.00	0.00			
(d) Current Tax Liabilities (Net)	95.00	0.00	95.00	122.00	
<b>Sub Total - Current Liabilities</b>	<b>117.40</b>	<b>7.81</b>	<b>525.96</b>	<b>638.66</b>	
<b>Total Equity and Liabilities</b>	<b>6809.22</b>	<b>6162.54</b>	<b>12728.49</b>	<b>12598.64</b>	

DATE: 23.05.2024  
PLACE: INDORE

For and on behalf of board of directors of  
**MEDI-CAPS LIMITED**

  
**ALOK K GARG**  
 MANAGING DIRECTOR  
 DIN: 00274321



**MEDI-CAPS LIMITED**

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1,PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435


Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

AUDITED CONSOLIDATED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR QUARTER AND YEAR ENDED 31ST MARCH 2024

S.No.	Segment Revenue	Quarter Ended			Year Ended	
		03 Month Ended 31.03.2024	Preceeding 03 Month Ended 31.12.2023	Corresponding 03 Month Ended in the previous year 31.03.2023	Year Ended 31.03.2024	Previous Year Ended 31.03.2023
		Audited	Unaudited	Audited	Audited	Audited
1	<b>Segment Revenue</b>					
	Pharma Division	600.58	411.12	1071.93	2050.75	5022.83
	Real Estate Division	210.61	304.98	8.81	731.26	74.60
	Other	0.00	0.00	0.00	0.00	0.00
	<b>Net Sale/Income From Operations</b>	<b>811.19</b>	<b>716.10</b>	<b>1080.74</b>	<b>2782.01</b>	<b>5097.43</b>
2	<b>Segment Results (Profit) (+)/ Loss (-) before tax and Interest</b>					
	Pharma Division	-173.03	-179.47 *	82.45	-607.33	466.66
	Real Estate Division	114.12	213.61	-3.01	482.73	25.57
	Other	0.00	0.00	0.00	0.00	0.00
	<b>Total</b>	<b>-58.90</b>	<b>34.14</b>	<b>79.44</b>	<b>-124.60</b>	<b>492.23</b>
	Interest Income	0.00	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	0.00	0.01	0.00	0.16
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00	0.00
	<b>Profit Before Tax</b>	<b>-58.90</b>	<b>34.14</b>	<b>79.43</b>	<b>-124.60</b>	<b>492.07</b>
3	<b>Capital Employed</b>					
	<b>Segment Assets (A)</b>					
	Pharma Division	5919.27	5876.78	12434.16	5919.27	12434.16
	Real Estate Division	6809.22	6667.20	164.48	6809.22	164.48
	Other	0.00	0.00	0.00	0.00	0.00
	<b>Total (A)</b>	<b>12728.49</b>	<b>12543.98</b>	<b>12598.64</b>	<b>12728.49</b>	<b>12598.64</b>
	<b>Segment Liabilities (B)</b>					
	Pharma Division	469.86	326.53	741.50	469.86	741.50
	Real Estate Division	160.30	111.53	0.00	160.30	0.00
	Other	0.00	0.00	0.00	0.00	0.00
	<b>Total (B)</b>	<b>630.16</b>	<b>438.06</b>	<b>741.50</b>	<b>630.16</b>	<b>741.50</b>
4	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>					
	Pharma Division	5449.41	5550.25	11692.66	5449.41	11692.66
	Real Estate Division	6648.92	6555.67	164.48	6648.92	164.48
	Other	0.00	0.00	0.00	0.00	0.00
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>	<b>12098.33</b>	<b>12105.92</b>	<b>11857.14</b>	<b>12098.33</b>	<b>11857.14</b>

DATE: 23.05.2024  
PLACE: INDORE

For and on behalf of board of directors of  
**MEDI-CAPS LIMITED**



**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321

## MEDI-CAPS LIMITED

REGD. OFFICE: MHOW-NEEMUCH ROAD, SECTOR-1, PITHAMPUR-454775, DISTT. DHAR (M.P.), Tel: 07292-256205, Fax: 0731-4041435  
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231


**AUDITED STANDALONE AND CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2024**

(Amount in Lakhs)

PARTICULARS	Standalone		Consolidated	
	For the Year Ended 31st March 2024	For the Year Ended 31st March 2023	For the Year Ended 31st March 2024	For the Year Ended 31st March 2023
	Audited	Audited	Audited	Audited
<b>A. Cash Flow from Operating Activities</b>				
Net Profit/(Loss) before Tax & Extraordinary Items	482.73	-25.57	(124.60)	492.07
Adjustment For:				
Depreciation	16.01	16.01	168.65	181.10
Dividend Income	0.00	0.00	(0.44)	(0.28)
Other Comprehensive Income	149.36	-32.70	465.27	55.95
Profit/(Loss) from Discontinue Operation	0.00	-11.07	(0.00)	(11.07)
<b>Operating Profit before Working Capital Change</b>	<b>648.10</b>	<b>(2.19)</b>	<b>508.88</b>	<b>717.77</b>
Adjustment for Working Capital	0.00	0.00	0.00	0.00
(Increase)/ Decrease in Sundry Debtors	(241.22)	0.33	(235.27)	160.75
(Increase)/ Decrease in Inventories	(3.16)	0.00	133.31	478.08
(Increase)/ Decrease in Loans & Advances	(108.93)	(257.97)	497.76	(991.34)
Increase in Current Liabilities & Provisions	109.60	0.19	(110.26)	(667.80)
<b>Cash Generated from Working Capital</b>	<b>(243.71)</b>	<b>(257.45)</b>	<b>285.54</b>	<b>(1020.32)</b>
<b>Cash generated from Operation</b>	<b>404.38</b>	<b>(259.63)</b>	<b>794.42</b>	<b>(302.55)</b>
Net Income Tax Paid	95.00	0.00	100.56	305.58
<b>Net cash Flow from Operating Activity</b>	<b>309.38</b>	<b>(259.63)</b>	<b>693.86</b>	<b>(608.12)</b>
<b>B. Cash Flow from Investing Activities</b>				
Proceed from Sale/purchase of Fixed Assets	4.36	15.00	(34.58)	(116.28)
Purchase/Sale of Investment	(313.25)	170.00	(738.93)	(140.02)
Dividend Received	0.00	0.00	0.44	0.28
<b>Net Cash used in Investing Activities</b>	<b>(308.89)</b>	<b>185.00</b>	<b>(773.07)</b>	<b>(256.02)</b>
<b>C. Cash Flow from Financial Activities</b>				
Increase in Long term borrowing	0.00	0.00	0.00	0.00
<b>Net Cash Used in Financial Activities</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>Net Increase in Cash and Cash Equivalents (A+B+C)</b>	<b>0.49</b>	<b>(74.63)</b>	<b>(79.21)</b>	<b>(864.14)</b>
Cash & Cash Equivalents at the				
Beginning of the year	4.05	78.68	111.35	975.49
Closing of the year	4.54	4.05	32.14	111.35
<b>Increase in Cash and Cash Equivalents</b>	<b>0.49</b>	<b>(74.63)</b>	<b>(79.21)</b>	<b>(864.14)</b>

DATE: 23.05.2024  
PLACE: INDORE

For and on behalf of board of directors of  
MEDI-CAPS LIMITED



**ALOK K GARG**  
MANAGING DIRECTOR  
DIN: 00274321


**NOTES:**

1. The above standalone and consolidated Audited financial results for the Quarter and Financial Year ended March 31, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on May 23, 2024. The statutory auditors have expressed an unmodified opinion for financial results for year ended 31<sup>st</sup> March, 2024 therefore the Company is not required to give statement of impact of Audit Qualification for Audit Report with modified opinion.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
3. The above consolidated results included the result of wholly owned subsidiary company i.e. Medgel Private Limited.
4. The Company has two reportable segments for the Consolidated Financial Statements which consists of Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and same is enclosed with this result.
5. The standalone and consolidated statement of assets & Liabilities as at March 31, 2024 is annexed with the results along with cash flow statements.
6. The Company has generated revenue from sales of shops of Medicaps Business Park of Rs. 184.29 Lacs during this quarter and Rs. 693.03 Lacs during F.Y. 2023-24.
7. The consolidated profit decreased due to lower subsidiary revenue resulting from a USFDA warning letter, as mentioned in previous quarters. However, the management is committed to resolving the issue as efficiently as possible. The Medgel team has been diligently working on every key initiative to ensure full compliance with the requirements of the warning letter.
8. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.
9. The Statement includes the results for the quarters ended March 31, 2024 and March 31, 2023 being the balancing figure of the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the respective financial years, the results of which were subjected to 'limited review'.
10. The aforesaid audited financial Results will be uploaded on the Company's website [www.medicaps.com](http://www.medicaps.com) and will also be available on the websites of the Stock exchange i.e. [www.bseindia.com](http://www.bseindia.com) for the benefit of shareholders and investors.

**DATE: 23.05.2024**  
**PLACE: INDORE**

**For and on behalf of the Board of Directors of**

**MEDI-CAPS LIMITED**

  
**ALOK K GARG**  
**MANAGING DIRECTOR**  
**DIN: 00274321**



# **MC** MEDI-CAPS LIMITED

**Regd. Office and works:**

Mhow - Neemuch Road, Sector 1, CIN: L70100MP1983PLC002231  
Pithampur - 454775, Dist. Dhar  
Madhya Pradesh, India

Ph:- 07292-256205

Fax:- 0731-4041435

E mail:- [investors@medicaps.com](mailto:investors@medicaps.com)

Web site:- [www.medicaps.com](http://www.medicaps.com)

**MCL/SE/2024-2025**

**Date: 23<sup>rd</sup> May, 2024**

**Online filing at: [www.listing.bseindia.com](http://www.listing.bseindia.com)**

To,  
The General Manager  
DCS-CRD  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street Fort, Mumbai – 400001(M.H.)

**Subject: Submission of declaration regarding unmodified opinion of the Auditors on Annual Audited Standalone and Consolidated Financial Results of the Company for the year ended 31<sup>st</sup> March, 2024 as per second proviso to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.**

**Reference: MEDI-CAPS LIMITED (BSE Scrip Code: 523144, ISIN: INE442D01010)**

## **DECLARATION**

Pursuant to Regulation 33(3) (d) of **Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**, as amended from time to time, the undersigned do hereby declare that in the Audit Report, accompanying the standalone as well as consolidated Annual Audited Financial results of the **Medi-Caps Limited** for the financial year ended on **31<sup>st</sup> March, 2024**, the Statutory Auditor Rawka & Associates, did not express any modified opinion/Audit qualification/or other reservation and accordingly, the statement on impact of audit qualification is not required to be given.

Further, aforesaid declaration shall also be submitted in XBRL mode within prescribed time limit.

You are requested to please consider and take on record the same.

Thanking You,  
Yours Faithfully,


**For, MEDI-CAPS LIMITED**

**ALOK K GARG** (Managing Director)  
DIN 00274321

**HEMANT SETHI** (CFO)

**ASHOK OMPRAKASH AGRAWAL** (Audit Committee Chairman)  
DIN 07870578

**RAWKA & ASSOCIATES**  
CHARTERED ACCOUNTANTS  
FRN: 021606C  
VENUS RAWKA  
PARTNER  
M. NO.: 429040



*Corporate Office: 201, Pushpratna Paradise 9/5 New Palasiya,  
Opposite UCO Bank Indore (M.P.) 452001; Contact No: 0731-4028148*